A categorical structure-activity relationship analysis of GPR119 ligands

被引:1
作者
Kumar, Pritesh [1 ]
Carrasquer, Carl A. [2 ,3 ]
Carter, Arren [3 ,4 ]
Song, Zhao-Hui [1 ]
Cunningham, Albert R. [1 ,2 ,3 ]
机构
[1] Univ Louisville, Dept Pharmacol & Toxicol, Louisville, KY 40292 USA
[2] Univ Louisville, Dept Med, Louisville, KY 40292 USA
[3] Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40292 USA
[4] Univ Louisville, Dept Chem, Louisville, KY 40292 USA
基金
美国国家卫生研究院;
关键词
categorical structure-activity relationship (cat-SAR); structure-activity relationship (SAR); fragment-based modelling; G protein-coupled receptor 119 (GPR119); diabetes; PROTEIN-COUPLED RECEPTOR; AGONISTS; POTENT; IDENTIFICATION; JNJ-38431055; DISCOVERY; MODEL;
D O I
10.1080/1062936X.2014.967292
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The categorical structure-activity relationship (cat-SAR) expert system has been successfully used in the analysis of chemical compounds that cause toxicity. Herein we describe the use of this fragment-based approach to model ligands for the G protein-coupled receptor 119 (GPR119). Using compounds that are known GPR119 agonists and compounds that we have confirmed experimentally that are not GPR119 agonists, four distinct cat-SAR models were developed. Using a leave-one-out validation routine, the best GPR119 model had an overall concordance of 99%, a sensitivity of 99%, and a specificity of 100%. Our findings from the in-depth fragment analysis of several known GPR119 agonists were consistent with previously reported GPR119 structure-activity relationship (SAR) analyses. Overall, while our results indicate that we have developed a highly predictive cat-SAR model that can be potentially used to rapidly screen for prospective GPR119 ligands, the applicability domain must be taken into consideration. Moreover, our study demonstrates for the first time that the cat-SAR expert system can be used to model G protein-coupled receptor ligands, many of which are important therapeutic agents.
引用
收藏
页码:891 / 903
页数:13
相关论文
共 25 条
  • [1] Biology of incretins: GLP-1 and GIP
    Baggio, Laurie L.
    Drucker, Daniel J.
    [J]. GASTROENTEROLOGY, 2007, 132 (06) : 2131 - 2157
  • [2] A role for β-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release
    Chu, Zhi-Liang
    Jones, Robert M.
    He, Hongmei
    Carroll, Chris
    Gutierrez, Veronica
    Lucman, Annette
    Moloney, Molly
    Gao, Hui
    Mondala, Helen
    Bagnol, Didier
    Unett, David
    Liang, Yin
    Demarest, Keith
    Semple, Graeme
    Behan, Dominic P.
    Leonard, James
    [J]. ENDOCRINOLOGY, 2007, 148 (06) : 2601 - 2609
  • [3] Structure-Activity Relationship Analysis of Rat Mammary Carcinogens
    Cunningham, Albert R.
    Moss, Sharma T.
    Iype, Seena A.
    Qian, Gefei
    Qamar, Shahid
    Cunningham, Suzanne L.
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 2008, 21 (10) : 1970 - 1982
  • [4] A Categorical Structure-Activity Relationship Analysis of the Developmental Toxicity of Antithyroid Drugs
    Cunningham, Albert R.
    Carrasquer, C. Alex
    Mattison, Donald R.
    [J]. INTERNATIONAL JOURNAL OF PEDIATRIC ENDOCRINOLOGY, 2009,
  • [5] Development of an information-intensive structure-activity relationship model and its application to human respiratory chemical sensitizers
    Cunningham, AR
    Cunningham, SL
    Consoer, DM
    Moss, ST
    Karol, MH
    [J]. SAR AND QSAR IN ENVIRONMENTAL RESEARCH, 2005, 16 (03) : 273 - 285
  • [6] THE SIGNIFICANCE OF GPR119 AGONISTS AS A FUTURE TREATMENT FOR TYPE 2 DIABETES
    Dhayal, Shalinee
    Morgan, Noel G.
    [J]. DRUG NEWS & PERSPECTIVES, 2010, 23 (07) : 418 - 424
  • [7] GPR119 Regulates Murine Glucose Homeostasis Through Incretin Receptor-Dependent and Independent Mechanisms
    Flock, Grace
    Holland, Dianne
    Seino, Yutaka
    Drucker, Daniel J.
    [J]. ENDOCRINOLOGY, 2011, 152 (02) : 374 - 383
  • [8] The Emergence of GPR119 Agonists as Anti-Diabetic Agents
    Jones, Robert M.
    Leonard, James N.
    [J]. ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 44, 2009, 44 : 149 - 170
  • [9] GPR119 agonists for the treatment of type 2 diabetes
    Jones, Robert M.
    Leonard, James N.
    Buzard, Daniel J.
    Lehmann, Juerg
    [J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2009, 19 (10) : 1339 - 1359
  • [10] Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes
    Katz, L. B.
    Gambale, J. J.
    Rothenberg, P. L.
    Vanapalli, S. R.
    Vaccaro, N.
    Xi, L.
    Sarich, T. C.
    Stein, P. P.
    [J]. DIABETES OBESITY & METABOLISM, 2012, 14 (08) : 709 - 716